Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors-Reference-Cited by-同舟云学术

Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

Published:2014-11-11 Issue:1 Volume:13 Page:72-81
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Zakas P. M.¹,Vanijcharoenkarn K.²,Markovitz R. C.²³,Meeks S. L.⁴,Doering C. B.⁴

Affiliation:

1. Graduate Program in Molecular and Systems Pharmacology; Laney Graduate School; Emory University; Atlanta GA USA

2. School of Medicine; Emory University; Atlanta GA USA

3. Graduate Program in Immunology and Molecular Pathogenesis; Laney Graduate School; Emory University; Atlanta GA USA

4. Aflac Cancer and Blood Disorders Center; Emory University/Children's Healthcare of Atlanta; Atlanta GA USA

Funder

National Institute of Health

Hemophilia of Georgia

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.12755/fullpdf

Reference43 articles.

1. A study of variations in the reported haemophilia A prevalence around the world;Stonebraker;Haemophilia,2010

2. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation;Collins;Blood,2007

3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

4. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

5. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A;Lusher;Haemophilia,2003

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay;Research and Practice in Thrombosis and Haemostasis;2022-11

2. Molecular coevolution of coagulation factor VIII and von Willebrand factor;Blood Advances;2021-02-05

3. Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII;Molecular Therapy - Methods & Clinical Development;2020-06

4. 3D-printed graphene for bone reconstruction;2D Materials;2020-02-14

5. Elimination of factor VIII-specific B cells by immunotoxins composed of a single factor VIII domain fused toPseudomonasexotoxin A;Journal of Thrombosis and Haemostasis;2018-10-08